660 related articles for article (PubMed ID: 17697087)
1. Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda.
Liechty CA; Solberg P; Were W; Ekwaru JP; Ransom RL; Weidle PJ; Downing R; Coutinho A; Mermin J
Trop Med Int Health; 2007 Aug; 12(8):929-35. PubMed ID: 17697087
[TBL] [Abstract][Full Text] [Related]
2. Cryptococcal antigenemia in anti-retroviral naïve AIDS patients: prevalence and its association with CD4 cell count.
Osazuwa OF; Dirisu O; Okuonghae E
Acta Med Iran; 2012; 50(5):344-7. PubMed ID: 22837089
[TBL] [Abstract][Full Text] [Related]
3. Cryptococcal disease in patients with or without human immunodeficiency virus: clinical presentation and monitoring of serum cryptococcal antigen titers.
Lin TY; Yeh KM; Lin JC; Wang NC; Peng MY; Chang FY
J Microbiol Immunol Infect; 2009 Jun; 42(3):220-6. PubMed ID: 19812855
[TBL] [Abstract][Full Text] [Related]
4. Cryptococcal antigenemia is associated with meningitis or death in HIV-infected adults with CD4 100-200 cells/mm
Wykowski J; Galagan SR; Govere S; Wallis CL; Moosa MY; Celum C; Drain PK
BMC Infect Dis; 2020 Jan; 20(1):61. PubMed ID: 31959112
[TBL] [Abstract][Full Text] [Related]
5. [Disseminated cryptococcosis in patients with AIDS. Clinical, microbiological, and immunological analysis of 51 patients].
Metta HA; Corti ME; Negroni R; Helou S; Arechavala A; Soto I; Villafañe MF; Muzzio E; Castello T; Esquivel P; Trione N
Rev Argent Microbiol; 2002; 34(3):117-23. PubMed ID: 12415893
[TBL] [Abstract][Full Text] [Related]
6. Prevalence and outcomes of cryptococcal antigenemia in HIV-seropositive patients hospitalized for suspected tuberculosis in Uganda.
Andama AO; den Boon S; Meya D; Cattamanchi A; Worodria W; Davis JL; Walter ND; Yoo SD; Kalema N; Haller B; Huang L;
J Acquir Immune Defic Syndr; 2013 Jun; 63(2):189-94. PubMed ID: 23542636
[TBL] [Abstract][Full Text] [Related]
7. Implementation and operational research: Integrated pre-antiretroviral therapy screening and treatment for tuberculosis and cryptococcal antigenemia.
Pac L; Horwitz MM; Namutebi AM; Auerbach BJ; Semeere A; Namulema T; Schwarz M; Bbosa R; Muruta A; Meya DB; Manabe YC
J Acquir Immune Defic Syndr; 2015 Apr; 68(5):e69-76. PubMed ID: 25761234
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcome of AIDS-associated cryptococcosis in the era of combination antiretroviral therapy.
Lortholary O; Poizat G; Zeller V; Neuville S; Boibieux A; Alvarez M; Dellamonica P; Botterel F; Dromer F; Chêne G
AIDS; 2006 Nov; 20(17):2183-91. PubMed ID: 17086058
[TBL] [Abstract][Full Text] [Related]
9. The role of serum cryptococcal antigen screening for the early diagnosis of cryptococcosis in HIV-infected patients with different ranges of CD4 cell counts.
Pongsai P; Atamasirikul K; Sungkanuparph S
J Infect; 2010 Jun; 60(6):474-7. PubMed ID: 20347868
[TBL] [Abstract][Full Text] [Related]
10. No association of cryptococcal antigenemia with poor outcomes among antiretroviral therapy-experienced HIV-infected patients in Addis Ababa, Ethiopia.
Smitson CC; Tenna A; Tsegaye M; Alemu AS; Fekade D; Aseffa A; Blumberg HM; Kempker RR
PLoS One; 2014; 9(1):e85698. PubMed ID: 24465651
[TBL] [Abstract][Full Text] [Related]
11. Prevalence and mortality of cryptococcal disease in adults with advanced HIV in an urban tertiary hospital in Sierra Leone: a prospective study.
Lakoh S; Rickman H; Sesay M; Kenneh S; Burke R; Baldeh M; Jiba DF; Tejan YS; Boyle S; Koroma C; Deen GF; Beynon F
BMC Infect Dis; 2020 Feb; 20(1):141. PubMed ID: 32059703
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of a national cryptococcal antigen screening program for HIV-infected patients in Uganda: A cost-effectiveness modeling analysis.
Rajasingham R; Meya DB; Greene GS; Jordan A; Nakawuka M; Chiller TM; Boulware DR; Larson BA
PLoS One; 2019; 14(1):e0210105. PubMed ID: 30629619
[TBL] [Abstract][Full Text] [Related]
13. Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa.
Moh R; Danel C; Messou E; Ouassa T; Gabillard D; Anzian A; Abo Y; Salamon R; Bissagnene E; Seyler C; Eholié S; Anglaret X
AIDS; 2007 Nov; 21(18):2483-91. PubMed ID: 18025885
[TBL] [Abstract][Full Text] [Related]
14. Asymptomatic cryptococcal antigen prevalence detected by lateral flow assay in hospitalised HIV-infected patients in São Paulo, Brazil.
Vidal JE; Toniolo C; Paulino A; Colombo A; Dos Anjos Martins M; da Silva Meira C; Pereira-Chioccola VL; Figueiredo-Mello C; Barros T; Duarte J; Fonseca F; Alves Cunha M; Mendes C; Ribero T; Dos Santos Lazera M; Rajasingham R; Boulware DR
Trop Med Int Health; 2016 Dec; 21(12):1539-1544. PubMed ID: 27699970
[TBL] [Abstract][Full Text] [Related]
15. Serum cryptococcal antigen titre as a diagnostic tool and a predictor of mortality in HIV-infected patients with cryptococcal meningitis.
Chen J; Zhang R; Shen Y; Liu L; Qi T; Wang Z; Mehraj V; Routy JP; Lu H
HIV Med; 2019 Jan; 20(1):69-73. PubMed ID: 30311440
[TBL] [Abstract][Full Text] [Related]
16. Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: an international observational study.
Mussini C; Pezzotti P; Miró JM; Martinez E; de Quiros JC; Cinque P; Borghi V; Bedini A; Domingo P; Cahn P; Bossi P; de Luca A; d'Arminio Monforte A; Nelson M; Nwokolo N; Helou S; Negroni R; Jacchetti G; Antinori S; Lazzarin A; Cossarizza A; Esposito R; Antinori A; Aberg JA;
Clin Infect Dis; 2004 Feb; 38(4):565-71. PubMed ID: 14765351
[TBL] [Abstract][Full Text] [Related]
17. Prevalence, incidence and mortality associated with tuberculosis in HIV-infected patients initiating antiretroviral therapy in rural Uganda.
Moore D; Liechty C; Ekwaru P; Were W; Mwima G; Solberg P; Rutherford G; Mermin J
AIDS; 2007 Mar; 21(6):713-9. PubMed ID: 17413692
[TBL] [Abstract][Full Text] [Related]
18. Immunological profiles of immune restoration disease presenting as mycobacterial lymphadenitis and cryptococcal meningitis.
Tan DB; Yong YK; Tan HY; Kamarulzaman A; Tan LH; Lim A; James I; French M; Price P
HIV Med; 2008 May; 9(5):307-16. PubMed ID: 18400078
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings.
Meya DB; Manabe YC; Castelnuovo B; Cook BA; Elbireer AM; Kambugu A; Kamya MR; Bohjanen PR; Boulware DR
Clin Infect Dis; 2010 Aug; 51(4):448-55. PubMed ID: 20597693
[TBL] [Abstract][Full Text] [Related]
20. Reflexive Laboratory-Based Cryptococcal Antigen Screening and Preemptive Fluconazole Therapy for Cryptococcal Antigenemia in HIV-Infected Individuals With CD4 <100 Cells/µL: A Stepped-Wedge, Cluster-Randomized Trial.
Meya DB; Kiragga AN; Nalintya E; Morawski BM; Rajasingham R; Park BJ; Mubiru A; Kaplan JE; Manabe YC; Boulware DR
J Acquir Immune Defic Syndr; 2019 Feb; 80(2):182-189. PubMed ID: 30399034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
